Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 9/20 | 0.34 |
| ▸ | TBXAS1 | P24557 | 3/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4569772 | 0.84 | SMN1; SMN2 (0.43) | HSP90AA1BRD4NPC1RAB9A | |
| SCHEMBL10150150 | 0.83 | SLC2A1 (0.37) | CYP19A1TBXAS1SLC2A1HSP90AA1HSP90AB1 | |
| SCHEMBL3706703 | 0.76 | L3MBTL1 (0.41) | TBXAS1BRD4ATM | |
| SCHEMBL4569769 | 0.76 | KDM4E (0.41) | BRD4NPC1RAB9A | |
| SCHEMBL4569768 | 0.74 | FEN1 (0.40) | — | |
| SCHEMBL3698821 | 0.67 | L3MBTL1 (0.36) | SLC2A1HSP90AA1HSP90AB1BRD4 | |
| SCHEMBL3969618 | 0.65 | NCF1 (0.49) | SLC2A1NPC1RAB9A | |
| SCHEMBL5959744 | 0.65 | HTR6 (0.46) | CYP19A1SLC2A1 | |
| SCHEMBL4569764 | 0.64 | KMT2A (0.45) | HSP90AA1IDO1NPC1RAB9A | |
| SCHEMBL913801 | 0.64 | MPO (0.44) | CYP19A1TBXAS1PARP1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8648086-B2 | 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors | ASCEPION PHARMACEUTICALS, INC. (CN) | 2014-02-11 | — | — | US | disclosed |
| US-20120122895-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | JIANG, SHAN | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122895-A1 | 5,6-BICYCLIC HETEROARYL-CONTAINING UREA COMPOUNDS AS KINASE INHIBITORS | FLT3, CSF1R, EPHA2 | CYP19A1 2563/4885TBXAS1 1591/4885SLC2A1 3190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.